Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Transplantation of Haploidentical CD34+ Purified Peripheral Blood Stem Cells With NK-Cell Add-Back Following Conditioning With Total Body Irradiation, Thiotepa, Fludarabine and OKT3

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving a donor peripheral stem cell transplant and a donor natural killer cell transplant after total-body irradiation, thiotepa, fludarabine, and muromonab-CD3 works in treating patients with leukemia or other blood diseases.

Study Overview

• Status: Terminated
• Conditions: Myelodysplastic Syndromes; Leukemia; Graft Versus Host Disease
• Intervention / Treatment: Genetic: gene expression analysis; Drug: methotrexate; Drug: thiotepa; Drug: fludarabine phosphate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: in vitro-treated peripheral blood stem cell transplantation; Radiation: total-body irradiation; Other: flow cytometry; Other: immunologic technique; Biological: muromonab-CD3; Biological: natural killer cell therapy

Detailed Description

OBJECTIVES:

Primary

• Determine the effect of haploidentical donor CD34+ purified peripheral blood stem cells and donor natural killer (NK) cells on the risk of developing grades III-IV acute graft-vs-host disease in patients with leukemia or other hematologic diseases.

Secondary

• Determine the risk for mortality from infection before day 180 in patients treated with this regimen.
• Determine the risk for graft rejection in patients treated with this regimen.
• Determine the risk for life-threatening infections in patients treated with this regimen.
• Determine the concentration of subsets of NK, NK-T, T cells, and dendritic cells in the CD34+ NK/NK-T-enriched graft.
• Determine cytomegalovirus-specific T-cells in product and donor graft.
• Determine the genotype and phenotype of donor killer cell immunoglobulin-like receptor expression according to time after hematopoietic stem cell transplantation (HSCT).
• Determine the reconstitution of NK function according to time after HSCT.
• Determine the expression of NKG2 ligands of leukemic blasts.

OUTLINE: Patients are stratified according to age (≤ 7 years vs > 7 years).

• Conditioning regimen: Patients 7 years of age or younger undergo total-body irradiation (TBI) twice daily on days -11 to -9. Patients over 7 years of age undergo TBI once on day -9. All patients receive thiotepa IV over 2 hours on days -8 and -7, fludarabine phosphate IV on days -6 to -3 and muromonab-CD3 on days -6 to 6. Patients with acute lymphoblastic leukemia or leukemia in the spinal fluid also receive methotrexate intrathecally prior to and after donor peripheral blood stem cell (PBSC) transplantation .
• Donor PBSC transplantation: Patients undergo donor PBSC transplantation comprising CD34+ purified PBSCs and natural killer (NK) cells on day 0.

Blood samples are collected in weeks 1-4, 6, 8, and 12. Analysis of samples includes quantitation of NK, NK-T, and T-cell subsets (CD3, CD4, and CD8) by flow cytometry; donor killer cell immunoglobulin-like receptor genotype and phenotype; interferon-gamma levels; and NK cytotoxicity. Samples are also analyzed by leukemic blast assay to determine if ligands that activate NK cells are expressed.

After completion of study therapy, patients are followed periodically.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98109-1023
      • Seattle Cancer Care Alliance
    • Seattle, Washington, United States, 98109-1024
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 45 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following life-threatening hematological malignancies:

  • Acute lymphoblastic leukemia meeting 1 of the following criteria:

    • Advanced beyond first remission

    • In first remission with high-risk prognostic features, including any of the following:

      • Philadelphia chromosome-positive disease
      • Chromosome 11q23 abnormality
      • Hypodiploid
      • Failed to achieve first remission within 1 month after induction

  • Acute myeloid leukemia (AML) meeting 1 of the following criteria:

    • Advanced beyond first remission

    • First remission with high-risk prognostic features, including any of the following:

      • Chromosome 11q23 abnormality
      • Chromosome del 7q
      • Secondary AML
      • Failed to achieve first remission within 1 month after induction
  • Myelodysplastic syndromes with International Prognostic Score > 1
  • Chronic myelogenous leukemia in accelerated or blastic phase
• No active CNS disease
• No suitable HLA-matched related or unrelated donor available

• Haploidentical family member available as donor of partially HLA-matched peripheral blood stem cells

  • Least degree of mismatch to HLA-A, B, C, DRB1, and DQB1
  • No mismatch for a single HLA-A, B, C, DRB1, or DQB1 antigen
  • Donor killer cell immunoglobulin-like receptor ligand group expression preferably different than patient

PATIENT CHARACTERISTICS:

• LVEF ≥ 45%
• DLCO ≥ 60% of predicted
• AST and ALT ≤ 2 times upper limit of normal (ULN) (unless due to malignancy)
• Bilirubin ≤ 2 times ULN (unless due to malignancy)
• No life expectancy < 6 months due to coexisting disease other than the malignancy
• No active infection (e.g., polymerase chain reaction [PCR] evidence for cytomegalovirus, human herpes virus 6, or invasive fungal infection)
• No prior infections without evidence of resolution by PCR or imaging studies within the past 2 months
• No hypersensitivity to murine antibodies
• No known HIV positivity
• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• No prior marrow transplantation with total body irradiation > 400 cGy
• No concurrent therapies for seizure disorder
• No growth factors for 21 days after transplantation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Risk of Developing Grades III-IV Acute Graft-vs-host Disease (GVHD)	Count of participants with acute GVHD grades III-IV.	Up to day 100

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Risk for Mortality From Infection Before Day 180	Count of participant deaths from infection up to day 180.	Up to day 180
Risk for Graft Failure	Count of participant that had graft failure.	Engraftment documented day +20
Risk for Life-threatening Infections	Count of participants with life-threatening infections	Up to day 100
Concentration of NK, NK-T, T-cells, and Dendritic Cell Subsets in the CD34+ NK/NK-T-enriched Graft		Up to 5 years
Cytomegalovirus-specific T Cells in Product and Donor Graft		Up to 5 years
Genotype and Phenotype of Donor Killer Cell Immunoglobulin-like Receptor Expression According to Time After Hematopoietic Stem Cell Transplantation (HSCT)		Up to 5 years
Reconstitution of NK Function According to Time After HSCT		Up to 5 years
Expression of NKG2 Ligands of Leukemic Blasts		Up to 5 years

Collaborators and Investigators

• Sponsor: Fred Hutchinson Cancer Center
• Collaborators: National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID)
• Investigators: Principal Investigator: Ann Woolfrey, MD, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study record dates

Study Major Dates

• Study Start: December 1, 2006
• Primary Completion (Actual): July 1, 2010
• Study Completion (Actual): July 1, 2010

Study Registration Dates

• First Submitted: March 20, 2007
• First Submitted That Met QC Criteria: March 20, 2007
• First Posted (Estimate): March 22, 2007

Study Record Updates

• Last Update Posted (Actual): May 24, 2017
• Last Update Submitted That Met QC Criteria: April 17, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Keywords: de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(15;17)(q22;q12); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); secondary acute myeloid leukemia; childhood acute lymphoblastic leukemia in remission; childhood acute myeloid leukemia in remission; childhood chronic myelogenous leukemia; childhood myelodysplastic syndromes; recurrent adult acute myeloid leukemia; adult acute myeloid leukemia in remission; blastic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; recurrent adult acute lymphoblastic leukemia; recurrent childhood acute lymphoblastic leukemia; accelerated phase chronic myelogenous leukemia; adult acute lymphoblastic leukemia in remission; recurrent childhood acute myeloid leukemia; graft versus host disease
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Leukemia; Preleukemia; Graft vs Host Disease; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Fludarabine; Fludarabine phosphate; Methotrexate; Thiotepa; Muromonab-CD3
• Other Study ID Numbers: 1965.00; P30CA015704 (U.S. NIH Grant/Contract); R01AI053193 (U.S. NIH Grant/Contract); FHCRC-1965.00; CDR0000533834 (Registry Identifier: PDQ)